TABLE 1.
Baseline characteristics of patients who developed early (within 12 months) and late (after 12 months) de novo cancer post-transplant (n = 2,759).
| Early cancers (n = 243, n, %) | Late cancers (n = 2,516, n, %) | p-values | |
|---|---|---|---|
| Donor characteristics | |||
| Age (years, mean [SD]) | 42.3 (17.1) | 35.7 (18.6) | <0.001 |
| Female gender (n, %) | 118 (48.6) | 1004 (39.9) | 0.001 |
| Type | 0.03 | ||
| Deceased | 179 (73.7) | 1927 (76.6) | |
| Live | 64 (26.3) | 589 (23.4) | |
| Recipient characteristics | |||
| Age (years, mean [SD]) | 50.8 (15.4) | 45.3 (14.2) | <0.001 |
| Female gender (n, %) | 98 (40.3) | 1051 (41.8) | 0.66 |
| Race (n, %) | 0.61 | ||
| Caucasian | 208 (85.5) | 2224 (88.4) | |
| Aboriginals/Maori | 11 (4.6) | 87 (3.4) | |
| Others | 24 (9.9) | 205 (8.2) | |
| Diabetes (n, %) | 40 (16.5) | 265 (10.5) | 0.002 |
| Coronary artery disease (n, %) | 30 (12.3) | 152 (6.0) | <0.001 |
| Peripheral vascular disease (n, %) | 10 (4.1) | 80 (3.2) | 0.09 |
| Cerebrovascular disease (n, %) | 9 (3.7) | 41 (1.6) | 0.04 |
| Smoker (n, %) | 0.19 | ||
| Non- smokers | 116 (57.4) | 1008 (52.4) | |
| Former smokers | 67 (33.2) | 655 (34.0) | |
| Current smokers | 19 (9.4) | 262 (13.6) | |
| Cause of ESKD (n, %) | 0.03 | ||
| Glomerulonephritis | 104 (42.8) | 1186 (47.1) | |
| Cystic | 32 (13.2) | 374 (14.9) | |
| Diabetes | 30 (12.3) | 201 (8.0) | |
| Vascular | 16 (6.6) | 96 (3.8) | |
| Analgesic nephropathy | 11 (4.5) | 107 (4.3) | |
| Others | 50 (20.6) | 552 (21.9) | |
| Viral serology | |||
| CMV | <0.001 | ||
| Negative | 65 (26.7) | 565 (22.5) | |
| Positive | 138 (56.8) | 1143 (45.4) | |
| Unknown | 40 (16.5) | 808 (32.2) | |
| EBV | <0.001 | ||
| Negative | 43 (17.7) | 237 (9.4) | |
| Positive | 134 (55.1) | 1061 (42.1) | |
| Unknown | 66 (27.2) | 1218 (48.5) | |
| Immunology/transplant | |||
| Waiting time (days, mean [SD]) | 868 (777) | 774 (768) | 0.07 |
| Ischemic time (hours, mean [SD]) | 11.1 (7.4) | 12.5 (7.9) | 0.01 |
| Transplant era (n, %) | <0.001 | ||
| 1980-1989 | 30 (12.3) | 667 (26.5) | |
| 1990-1999 | 58 (23.9) | 998 (39.7) | |
| After 2000 | 155 (63.8) | 851 (33.8) | |
| Induction immunosuppression | <0.001 | ||
| None | 131 (54) | 1917 (76) | |
| Interleukin-2 receptor therapy | 102 (42) | 446 (18) | |
| T-cell depleting therapy | 10 (4) | 153 (6) | |
| Maintenance immunosuppression | |||
| Steroids (Prednisolone) | 226 (93) | 2245 (89) | 0.06 |
| Calcineurin inhibitors | <0.001 | ||
| None | 16 (7) | 297 (12) | |
| Cyclosporine | 145 (60) | 1833 (73)) | |
| Tacrolimus | 82 (33) | 386 (15) | |
| Anti-metabolites | <0.001 | ||
| None | 27 (11) | 321 (13) | |
| Azathioprine | 60 (25) | 1246 (49) | |
| Mycophenolate mofetil/sodium | 156 (64) | 949 (38) | |